Response to Papp et al's "Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies"

被引：0

作者：

Isaq, Nasro A. ^{[1
,2
]}

Link, Jenny L. ^{[1
]}

机构：

[1] Mayo Clin, Dept Dermatol, Rochester, MN USA

[2] 200 1st St SW, Rochester, MN 55905 USA

来源：

关键词：

atopic dermatitis; health care cost; insurance; JAK inhibitor; ruxolitinib;

D O I：

10.1016/j.jaad.2023.04.076

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：e19 / e20

页数：2

共 2 条

[1]

National Association of Insurance Commissioners, NAIC releases 2021 Market Share Data

Papp, Kim ;

Szepietowski, Jacek C. ;

Kircik, Leon ;

Toth, Darryl ;

Eichenfield, Lawrence F. ;

Forman, Seth B. ;

Kuligowski, Michael E. ;

Kallender, Howard ;

Sun, Kang ;

Ren, Haobo ;

Simpson, Eric L. .